Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Working Capital Changes (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Other Working Capital Changes for 7 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 55375.0% year-over-year to -$2.2 million, compared with a TTM value of -$2.1 million through Dec 2025, down 51500.0%, and an annual FY2025 reading of -$2.1 million, down 51500.0% over the prior year.
  • Other Working Capital Changes was -$2.2 million for Q4 2025 at Keros Therapeutics, down from -$402000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $9.8 million in Q3 2023 and bottomed at -$10.8 million in Q3 2024.
  • Average Other Working Capital Changes over 5 years is $527650.0, with a median of -$104000.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes soared 3969.81% in 2022, then plummeted 55375.0% in 2025.
  • Year by year, Other Working Capital Changes stood at -$2.9 million in 2021, then soared by 160.77% to $1.7 million in 2022, then tumbled by 130.85% to -$539000.0 in 2023, then surged by 100.74% to $4000.0 in 2024, then tumbled by 55375.0% to -$2.2 million in 2025.
  • Business Quant data shows Other Working Capital Changes for KROS at -$2.2 million in Q4 2025, -$402000.0 in Q3 2025, and $5.1 million in Q2 2025.